Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)John N. Allan, Daniel Helbig,Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta,Sarah C. Rutherford,Jia Ruan,John P. Leonard,Peter Martin,Richard R. FurmanBLOOD（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
